CER Daily Newsfeed

Comparing Ways To Reduce Medicine Use Among Older Adults With Type 2 Diabetes

(12/5, PCORI) comments “‘We've come a long way in terms of diabetes care,’ says Richard Grant, M.D., MPH. ‘But all of it has to be looked at through a different lens as people get older.’ As the principal investigator of the PCORI-funded patient-centered comparative clinical effectiveness research study ‘Comparing Two Ways To Reduce Medicine Use Among Older Patients With Type 2 Diabetes,’ Richard knows this concern is increasingly relevant as the U.S. population ages...PCORI funds patient-centered CER studies to help patients and those who care for them make better-informed decisions in situations like these. ‘There’s no algorithm to decide who needs these medications and who doesn’t,’ Richard explains. ‘There’s so much more to it than just the data available in a patient’s chart.’” Full

Exclusive: Trump Administration Pushes End-of-Term Deadline for 'Most Favored Nation' Promises

(12/4, Anna Brown, Endpoints News) reports “...Large pharma companies that have made ‘most favored nation’ deals with the White House will have until the end of President Donald Trump's current term to fulfill some of their commitments to invest in the US, according to a framework of the agreements reviewed by Endpoints News...According to the document, the government and the companies will agree ‘in good faith’ on the amount of money that needs to be spent ‘to transfer to the US the manufacture of all pharmaceutical products and ingredients’ that are imported and consumed in the US. Products that are exempt from the Commerce Department's ongoing trade investigation won't be included.” Subscription Required

New UK Cost-Effectiveness Thresholds Will Not Mean A Reprieve For Drugs Already Denied Reimbursement

(12/5, Francesca Bruce, Pink Sheet) reports “...Some companies in the UK undergoing a health technology appraisal by the HTA body, NICE, will see reimbursement recommendations for their products paused in the run up to the implementation of higher cost-effectiveness thresholds.” Subscription Required